Quality Evaluation of Chinese Diabetes Management Guidelines based on AGREE II and AGREE-China
DOI:
https://doi.org/10.54097/ajmss.v2i2.7670Keywords:
Guide quality evaluation, AGREE Ⅱ, AGREE-China, DiabetesAbstract
The purpose of this study is to verify the applicability of the Chinese clinical practice guideline evaluation tool (AGREE-China) by evaluating the diabetes mellitus (DM) guidelines, and to compare its characteristics with the clinical guideline research and evaluation tool II (AGREE II), in order to provide reference for clinical practice and subsequent revision of guidelines.
Downloads
References
Li Y, Teng D, Shi X, et al. “Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study,” BMJ, Vol. 369, pp. 997, 2020.
Cao Lizhen. “Analysis of common irrational medication problems in digestive internal medicine clinical patients with diabetes mellitus,” Diabetes New World, Vol. 20(18), pp. 195-196, 2017.
Zhang Yue, Zhang Shijing, Zhou Zhichao, et al. “Development and inspiration of international clinical guideline evaluation tools,” Chinese Journal of Medical Library and Information Science, Vol. 24(01), pp. 11-16, 2015.
Wang Liying, Liu Mengyu, Wang Yuexi, et al. “Review on the evaluation status of clinical diagnosis and treatment guidelines in China,” Chinese Journal of Traditional Chinese Medicine, Vol. 31(4), pp. 1316-1319, 2016.
Wang Ji-yao, Wang Qiang, Wang Xiao-qin, et al. “Development and preliminary validation of the appraisal of China's clinical practice guidelines evaluation system,” Chinese Medical Journal, Vol. 98(20), pp. 1544-1548, 2018.
Scientific A. Appraisal of guidelines for research & evaluation II instrument. [Online]. Available: https://www.agreetrust.org/.
Pleil Joachim D and Sobus Jon R. “Estimating lifetime risk from spot biomarker data and intraclass correlation coefficients (ICC),” Journal of Toxicology and Environmental Health. Part A, Vol. 76(12), pp. 747-66, 2013.
Chinese Diabetes Society Microvascular Complication Study Group. “ Chinese guidelines for the prevention and treatment of diabetic kidney disease (2021 edition),” Chinese Journal of Diabetes, Vol. 13(8), pp. 762-784, 2021.
Chinese Medical Association, Chinese Medical Association Clinical Pharmacy Branch, Chinese Medical Association Journal Society, et al. “ Guidelines for rational drug use in type 2 diabetes mellitus,” Chinese Journal of General Practitioners, Vol. 20(6), pp. 615-630, 2021.
Chinese Diabetes Society, National Office for Primary Diabetes Prevention and Control, et al. “ Guidelines for primary diagnosis and treatment of type 2 diabetes (practice edition 2019),” Chinese Journal of General Practitioners, Vol. 18(9), pp. 810-818, 2019.
Chinese Diabetes Society, National Office for Primary Diabetes Prevention and Control Management. “ National primary diabetes prevention and management guidelines (2022),” Chinese Journal of Internal Medicine, Vol. 61(3), pp. 249-262. 2022.
Chinese Diabetes Society. “ Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition),” International Journal of Endocrinology and Metabolism, Vol. 41(5), pp. 482-548. 2021.
China National Working Group on Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly, Chinese Geriatric Society of Endocrinology and Metabolism, Chinese Society of Geriatrics of Health Care Medicine, et al. “ Clinical guidelines for the prevention and treatment of type 2 diabetes in the elderly in China (2022 edition),” Chinese Journal of Internal Medicine, Vol. 61(1), pp. 12-50, 2022.
National Center of Gerontology, Chinese Medical Association Geriatrics Society, Chinese Association of Gerontology and Geriatrics Diabetes Professional Committee. “Chinese guidelines for the diagnosis and treatment of elderly diabetes (2021 edition),” Chinese Journal of Diabetes, Vol. 13(1), pp. 14-46, 2021.
Chinese Society of Nephrology, Expert Group of Diabetic Kidney Disease, “Chinese guidelines for the diagnosis and treatment of diabetic kidney disease,” Chinese Journal of Nephrology, Vol. 37(3), pp. 255-304, 2021.
Chinese Physician Association Integrative Medicine Branch Endocrinology and Metabolism Disease Professional Committee. “Diagnosis and treatment guidelines for diabetes combined with hyperlipidemia in TCM,” World Chinese Medicine, Vol. 16(16), pp. 2377-2385, 2021.
Yu Jiangyi, Ni Qing, Liu Su. “Guidelines for the diagnosis and treatment of diabetic nephropathy with syndrome differentiation in traditional Chinese medicine,” Chinese Journal of Traditional Chinese Medicine, Vol. 63(2), pp. 190-197, 2022.
Chen Qiu, Ni Qing, Liu Ya. “Guidelines for the diagnosis and treatment of diabetic retinopathy combined with disease-syndrome differentiation (2021-09-24),” World Chinese Medicine, Vol. 16(22), pp. 3270-3277, 2021.
Wang Xiuge, Ni Qing, Pang Guoming. “Guidelines for the diagnosis and treatment of diabetic peripheral neuropathy combined with disease-syndrome differentiation,” Chinese Journal of Traditional Chinese Medicine, Vol. 62(18), pp. 1648-1656, 2021.
Fang Chaohui, Wu Yiling, Zhao Jindong. “Guidelines for the clinical diagnosis and treatment of diabetic peripheral neuropathy in TCM (2016 edition),” Chinese Journal of Traditional Chinese Medicine, Vol. 58(7), pp. 625-630, 2017.
Pang Guoming, Ni Qing, Zhang Fang. “Guidelines for the diagnosis and treatment of type 2 diabetes with the combination of disease and syndrome,” Chinese Journal of Traditional Chinese Medicine, Vol. 62(4), pp. 361-368. 2021.
Sheng Yongcheng, Li Li, Wang Qin, et al. “Quality evaluation of Chinese guidelines and consensus on fragility fractures based on AGREE II and AGREE-China,” Chinese Journal of Evidence-Based Medicine, Vol. 22(3), pp. 351-359. 2022.
Jia Junhai, Yang Jingzhi, Liu Aiping, Di Baoshan, Tang Yan. “Methodological quality evaluation of clinical practice guidelines for hypertension,” China Medical Guide, Vol. 20(1), pp. 1-6. 2018.
Wang Ji-yao. “The "Chinese standard" for evaluating the development of clinical practice guidelines,” Chinese Medical Journal, Vol. 98(20), pp. 1542-1543. 2018.
Li Jingya, Zhang Juanjuan, An Ying, et al. “Quality evaluation of Chinese medicine guidelines and consensus on stroke disease,” Chinese Journal of Information on Traditional Chinese Medicine, Vol. 29(8), pp. 30-36. 2022.
Center for Guidelines and Standards Research, Chinese Medical Association; WHO Collaborating Center for Guideline Implementation and Knowledge Translation. “Quality evaluation report of the publication of the Chinese Medical Association series of journals,” Chinese Medical Journal, Vol. 101(24), pp. 1839-1847. 2021.
Ni Ming, Wang Linhui, Li Guangtao, Xu Hong, Lu Yao. “Quality assessment of Chinese guidelines/consensus related to the diagnosis and treatment of breast cancer based on AGREE-China,” Chinese Journal of Cancer, Vol. 31(10), pp. 828-838. 2022.
He Lanzhi, Zhou Pengxiang, Zhou Xin, et al. “Quality evaluation of guidelines and consensus on calcium and vitamin D supplementation in healthy children based on AGREE-China,” Journal of Drug Epidemiology, Vol. 31(6), pp. 410-415. 2022.
Zhang Jing, Li Xiaotong, Tang Qiyu, Yan Yingying, Zhai Suodi. “Quality evaluation of guidelines and consensus on pulmonary embolism based on AGREE II and AGREE-China,” Journal of Drug Epidemiology, Vol. 31(3), pp. 183-189. 2022.
Tian Zhikui, Wang Dongjun, Zhou Zonghui, et al. “Quality evaluation of domestic guidelines/consensus on pediatric cough diagnosis and treatment,” World Science and Technology-Modernization of Traditional Chinese Medicine, Vol. 23(9), pp. 3401-3407, 2021.
Sun Yang, Li Bin, Wang Jianru, et al. “Quality system evaluation and reflection on Chinese heart failure guidelines,” Liaoning Journal of Traditional Chinese Medicine, pp. 1-20, Oct. 6, 2022.
Liang Dandan, Wang Yunyun, Li Xuhui, et al. “Quality evaluation of domestic primary care guidelines,” Chinese Journal of Evidence-Based Cardiovascular Medicine, Vol. 14(5), pp. 531-539, 2022.
Jiang Pin, Tang Haiqin, He Wei, et al. “Analysis of the current status of chronic disease clinical guidelines in primary care at home and abroad,” Chinese Journal of Evidence-Based Cardiovascular Medicine, Vol. 7(4), pp. 439-443, 2015.
